The EFHD1 Knockout K-562 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population, designed to disrupt the EFHD1 gene in the K-562 human cell line. This product provides a loss-of-function model for investigating EFHD1-dependent cellular processes. The polyclonal nature ensures a heterogeneous pool of edited cells, enabling robust assessment of gene function without clonal selection bias. Researchers can utilize these cells to dissect EFHD1??s roles in actin cytoskeleton organization, cell migration, and mitochondrial apoptosis.
The host K-562 cell line is a well-established model derived from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in blast crisis. These BCR-ABL-positive lymphoblastoid cells exhibit hematopoietic progenitor-like characteristics and are capable of undergoing erythroid and myeloid differentiation. Their robust growth and genetic tractability make them an ideal vehicle for studying oncogenic signaling and differentiation pathways. The K-562 background provides a physiologically relevant context for examining EFHD1 function in a leukemic environment.
EFHD1 encodes a calcium-binding EF-hand domain protein that functions as a sensor of intracellular calcium ions. Mechanistically, EFHD1 promotes actin cytoskeleton remodeling and cell motility by interacting with profilin-2 (PFN2) and modulating Rho GTPase signaling via RAC1 and RhoA, leading to cofilin-mediated actin dynamics. Additionally, EFHD1 enhances mitochondrial apoptosis through facilitating BAX translocation to mitochondria, which triggers cytochrome c release and downstream caspase-3 activation. This apoptotic function is linked to PI3K/AKT signaling via regulation of AKT phosphorylation. Upstream, EFHD1 expression is regulated by the transcription factor SP1 and subject to DNA methylation.
In the K-562 leukemia model, disruption of EFHD1 allows detailed interrogation of its contributions to BCR-ABL-driven signaling networks, especially those governing cytoskeletal reorganization and cell survival. Given EFHD1??s documented roles in cancer cell migration and apoptosis, this knockout model is particularly valuable for dissecting mechanisms of leukemic cell dissemination and therapeutic resistance. The polyclonal format also enables studies of heterogeneous responses within a population, mirroring tumor heterogeneity.
Typical research applications include transwell migration assays to evaluate cell motility, flow cytometry-based apoptosis assays using fluorescent probes such as JC-1 for mitochondrial membrane potential, and co-immunoprecipitation to probe EFHD1 interactions with PFN2 or BAX. These cells are also suitable for western blotting and RT-qPCR to confirm target disruption and downstream pathway alterations. Additional uses encompass immunofluorescence for actin cytoskeleton visualization and drug resistance profiling in the context of tyrosine kinase inhibitors. This product serves as a versatile tool for cancer cell biology and drug discovery programs. For further details and technical support, please contact Ascent Research.
